Mackie Research Reports That They Have Downgraded Concordia Healthcare Corp (TSE:CXR) Shares


Concordia Healthcare Corp (TSE:CXR) Receives a Downgrade

In a recent research report announced on Today, research professionals at the Mackie Research stock research division downgraded the stock rating for Concordia Healthcare Corp (TSE:CXR) shares to a Hold.

From a total of 10 analysts covering Concordia Healthcare Corp (TSE:CXR) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is $77 while the lowest target price is $33.88. The mean of all analyst targets is $53.03 with a 83.20% above today’s ($49.81) stock price. Concordia Healthcare Corp was the topic of 7 analyst reports since August 11, 2015 according to the firm StockzIntelligence Inc. Scotia Capital maintained shares on September 9 with “Sector Outperform” rating.

Approximately 414,957 shares of stock traded hands. Concordia Healthcare Corp (TSE:CXR) has declined 38.03% since April 30, 2015 and is downtrending. It has underperformed by 37.74% the S&P500.

Mackie Research Reports That They Have Downgraded Concordia Healthcare Corp (TSE:CXR) Shares

Concordia Healthcare Corp. is a Canada diverse healthcare company. The company has a market cap of $2.53 billion. The Firm is focused on legacy pharmaceutical products and orphan drugs. It has 256.04 P/E ratio. The Firm operates through three divisions, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc., which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran , for treatment of partial seizures in adults with epilepsy.